GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadence Pharmaceuticals, Inc. (FRA:QEW) » Definitions » Cyclically Adjusted Price-to-FCF

Cadence Pharmaceuticals, (FRA:QEW) Cyclically Adjusted Price-to-FCF : (As of Sep. 23, 2024)


View and export this data going back to . Start your Free Trial

What is Cadence Pharmaceuticals, Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cadence Pharmaceuticals, Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Cadence Pharmaceuticals,'s Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadence Pharmaceuticals, Cyclically Adjusted Price-to-FCF Chart

Cadence Pharmaceuticals, Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cadence Pharmaceuticals, Quarterly Data
Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cadence Pharmaceuticals,'s Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Cadence Pharmaceuticals,'s Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cadence Pharmaceuticals,'s Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cadence Pharmaceuticals,'s Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Cadence Pharmaceuticals,'s Cyclically Adjusted Price-to-FCF falls into.



Cadence Pharmaceuticals, Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Cadence Pharmaceuticals,'s Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec13 is calculated as:

For example, Cadence Pharmaceuticals,'s adjusted Free Cash Flow per Share data for the fiscal year that ended in Dec13 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec13 (Change)*Current CPI (Dec13)
=-0.201/98.3259*98.3259
=-0.201

Current CPI (Dec13) = 98.3259.

Cadence Pharmaceuticals, Annual Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
200412 -2.317 80.290 -2.837
200512 -5.083 83.032 -6.019
200612 -6.460 85.142 -7.460
200712 -1.028 88.616 -1.141
200812 -1.034 88.697 -1.146
200912 -0.638 91.111 -0.689
201012 -0.960 92.474 -1.021
201112 -0.971 95.213 -1.003
201212 -0.588 96.871 -0.597
201312 -0.201 98.326 -0.201

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cadence Pharmaceuticals,  (FRA:QEW) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Cadence Pharmaceuticals, Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Cadence Pharmaceuticals,'s Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Cadence Pharmaceuticals, Business Description

Traded in Other Exchanges
N/A
Address
Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates mainly for use in the hospital setting. The Company's main activities are conducting research and development activities as well as conducting clinical trials. The company has in-licensed rights to products: Acetavance, an intravenous formulation of acetaminophen, and Omigard, an omiganan pentahydrochloride 1% aqueous gel. It in-licensed the exclusive United States, or U.S., and Canadian rights to Acetavance from Bristol-Myers Squibb Company, or BMS, which markets this product candidate in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. The Company is developing Acetavance, a proprietary intravenous formulation of acetaminophen, for the U.S. market for the treatment of acute pain and fever in adults and children. In its oral form, acetaminophen is the most widely used drug for the treatment of pain and fever in the U.S. The Company's licensor, BMS, currently markets this proprietary intravenous formulation of acetaminophen for the treatment of acute pain and fever in Europe and several other markets outside the U.S, where it is known as paracetamol and is marketed under the brand name Perfalgan.

Cadence Pharmaceuticals, Headlines

No Headlines